Talk:Targeted therapy

Progress and future
The mention of only cannabidiol seems unbalanced. It might be better if we could list targeted therapies in say phase III clinical trials here (if there is no better place) ? Rod57 (talk) 05:57, 28 November 2008 (UTC)
 * How about just deleting the example entirely? Adding an example (any example) doesn't really help the reader understand the concept in this case.  (I'm not sure that the cannabidiol example is actually accurate.  It sounds like it's just low-side-effects systemic therapy.)  WhatamIdoing (talk) 02:59, 2 December 2008 (UTC)
 * Agreed on all points - it is a systemic therapy, removed. Rdbbbbbb (talk) 19:01, 5 April 2010 (UTC)
 * Happy with removal, but not sure a systemic therapy can't also be aimed at a molecular target. Rod57 (talk) 15:53, 14 February 2011 (UTC)
 * Should Synta Pharma's ganetespib now be cited in the Small Molecule section? Ganetespib is a unique Triazolone-containing Hsp90 inhibitor, now in phase 2/3 NSCLC trials. If my reading of recent reports is correct, this drug is showing rather considerable promise: (http://clinicaltrials.gov/ct2/show/NCT01348126?intr="STA-9090"&rank=15): efficacy with no ocular or renal toxicity in sizable targeted groups of patients with late stage lung carcinomas that have been unresponsive to other therapies. Ganetespib is a potent inhibitor of Hsp90, structurally unrelated to first-generation ansamycin-family Hsp90 inhibitors, being evaluated in 20+ clinical trials, either ongoing, or initiating, with the most advanced being the Phase 2b/3 GLAXAY trial evaluating ganetespib with docetaxel vs docetaxel alone in patients with advanced NSCLC who have progressed on first-line therapy. A global trial evaluating single-agent ganetespib in approximately 100 patients with ALK+ NSCLC who have not been previously treated with an ALK inhibitor is in the process of initiating. Frankatca (talk) 16:37, 6 March 2012 (UTC)
 * Targeted therapies lists so many FDA approved ones that it seems a distraction to try to list individual unapproved/experimental ones. It seems worth mentioning major categories in late stage clinical trials. I'm not sure salinomycin has a molecular target to qualify as a TT even if ever approved. - Rod57 (talk) 20:25, 12 October 2012 (UTC)

Only for cancer ?
The intro implies they are [only] for cancer. Can 'targeted therapy' not be used for say a targeted treatment for rheumatoid arthritis ? — Preceding unsigned comment added by Rod57 (talk • contribs) 15:35, 14 February 2011


 * In theory, it's possible for any type of disease. In practice, all of the examples I can think of offhand are—or were originally intended for—treatment of cancer.   WhatamIdoing (talk) 19:18, 15 February 2011 (UTC)

Announce changes
My name is Florian Schaub at Merck KGaA. My aim is to make some changes in this article. From our point of view colorectal cancer and head and neck cancer should be added to the third passage "There are targeted therapies...". In the passage "Monoclonal antibodies" we suggest adding a visual of the cetuximab MOA as an example on the TKI section. In the passage about the agents some changes on cetuximab and panitumumab about EGFR seem useful. Please let me know if anyone has concerns.

--Florian Schaub at Merck KGaA (talk) 10:15, 01 June 2016 (UTC)

Spam
User:Beetstra,

keeps adding links to

to this page. It's been reverted three times now. If it comes back, would you prefer that we request a block for the IP, or putting the URL on the spam blacklist? WhatamIdoing (talk) 19:34, 25 February 2020 (UTC)
 * , I’ll do the latter, it doesn’t look useful elsewhere, and communication is not their best feature. Dirk Beetstra T C 20:09, 25 February 2020 (UTC)
 * Thanks, Dirk. WhatamIdoing (talk) 20:27, 25 February 2020 (UTC)